NOTICE OF EXTRAORDINARY GENERAL MEETING
The board of directors of DiaGenic ASA (the “Company”) hereby summons for an extraordinary general meeting.
Time: 29 October 2010 at 10.00 hours (CET)
Place: Felix Konferansesenter, Bryggetorget 3, Oslo, Norway
Agenda:
- Opening of the meeting by chairman of the board Henrik Lund, including the taking of attendance of shareholders present
- Election of chairman of the meeting and a person to co-sign the minutes
- Approval of notice and agenda
- Share capital increase by issue of new shares (Private Placement)
- Share capital increase by issue of new shares (Repair Issue)
Please find attached notice to extraordinary general meeting. The notice will also be sent by mail to the Company’s shareholders.
Shareholders who cannot participate at the general meeting in person may authorize the chairman of the board or another person to vote for their shares by using the proxy form attached in the notice to extraordinary general meeting. The proxy form may be sent to the Company per e-mail to diagenic@diagenic.com, per fax +47 23 24 89 59 or be delivered to the proxy holder and brought to the general meeting.
Pursuant to the Company’s Articles of Association section 10, it is decided that shareholders and proxy holders who wish to participate at the general meeting, must notify the Company of his/her presence by use of the attendance form attached in the notice to extraordinary general meeting. Completed attendance form must be received by the Company within 27 October 2010.
Information regarding the extraordinary general meeting, including this notice with attachments and the Company’s Articles of Association, is available at the Company’s website www.diagenic.com.
Please contact Henrik Lund Chairman of the board, for more information regarding the extraordinary general meeting, phone +47 909 71 219
About DiaGenic ASA
DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for early detection of diseases. DiaGenic is currently a world leader in analyzing gene expression signatures related to disease in easily available clinical samples such as peripheral blood. This unique method is based on the principle that even when a disease is localized at a specific part of the body, secondary responses, which are also characteristic of the disease, can be measured in other parts of the body. DiaGenic has developed and CE marked two blood based diagnostic tests, BCtect® for early breast cancer detection and ADtect® for early detection of Alzheimer’s Disease. The company protects its technology through an extensive patent portfolio. DiaGenic promotes its products towards leading pharmaceutical and imaging companies, and towards clinicians. DiaGenic is listed on the Oslo Stock Exchange. For more information visit www.diagenic.com